Metastatic Cancer Clinical Trials in New York, New York

11 studies are recruiting for metastatic cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Memorial Sloan Kettering, New York, New York

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. FOG-001 in Locally Advanced or Metastatic Solid Tumors

   The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   33 in total

   Run by

   Parabilis Medicines, Inc.

   See if you can join NCT05919264 on ClinicalTrials.gov

3. A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

   Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05859074 on ClinicalTrials.gov

4. SLV-154 Treatment of Advanced Cancers

   This is a Phase 1 study comprising a Phase 1a dose-escalation portion and a Phase 1b expansion portion evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   10 in total

   Run by

   Solve Therapeutics

   See if you can join NCT06771219 on ClinicalTrials.gov

5. (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

   This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 482 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   126 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT05208047 on ClinicalTrials.gov

6. Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

   The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   VA New York Harbor Healthcare System, New York, New York

   Locations

   12 in total

   Run by

   Sun Pharmaceutical Industries Limited

   See if you can join NCT05422911 on ClinicalTrials.gov

7. Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer

   The study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (HRQoL…

   Stage

   Not phased

   Ages

   21 and older

   Site

   New York City Health and Hospitals, New York, New York

   Locations

   7 in total

   Run by

   Alliance Foundation Trials, LLC.

   See if you can join NCT06963723 on ClinicalTrials.gov

8. A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

   This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05010031 on ClinicalTrials.gov

9. Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

   This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NYU Langone, New York, New York

   Locations

   21 in total

   Run by

   I-Mab Biopharma US Limited

   See if you can join NCT04900818 on ClinicalTrials.gov

10. Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

    The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06058988 on ClinicalTrials.gov

11. Comprehensive Outcomes for After Cancer Health

    This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    7 in total

    Run by

    Pack Health

    See if you can join NCT05349227 on ClinicalTrials.gov